Skip to main content
. Author manuscript; available in PMC: 2024 Mar 29.
Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1640–1650. doi: 10.1158/1078-0432.CCR-21-2719

Figure 4:

Figure 4:

Overall survival in (A) all comers with non-squamous NSCLC, and (B) stage I-III, and (C) stage IV disease according to KRAS mutation status. Overall survival in (D) all comers with non-squamous NSCLC, and (E) stage I-III, and (F) stage IV disease according to KRAS alleles.